Dopamine D2 Receptor Blockade by Antipsychotics and Maintenance of Remission in Schizophrenia

Not Applicable

• Conditions: Schizophrenia

• Registration Number: JPRN-UMIN000006011
• Lead Sponsor: Keio University, School of Medicine Department of Neuropsychiatry

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2011-08-01
• Last Update Posted: 17 October 2023

Recruitment & Eligibility

• Status: Complete: follow-up complete
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

Not provided

Exclusion Criteria

(1) Receiving another antipsychotic drug (2) History of treatment with long-acting risperidone within 6 months (3) Past history of vagus nerve reflection with a blood test

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Positive and Negative Syndrome Scale (PANSS), Simpson-Angus Scale (SAS), Barnes Akathisia Rating Scale (BAS), Abnormal Involuntary Movement Scale (AIMS), Japanese version of the Calgary Depression Scale for Schizophrenics (JCDSS), Subjective Well-being under Neuroleptic drug treatment Short form, Japanese version (SWNS-J)

Secondary Outcome Measures

Name	Time	Method
Clinical Global Impression–Schizophrenia (CGI-SCH), Global Assessment of Functioning (GAF)